Discovery of novel CDK2 inhibitors for cancer treatment: integrating ligand-based pharmacophore modelling, molecular docking, DFT, ADMET, and molecular dynamics simulation studies

Abstract Background The global landscape of public health faces significant challenges attributed to the prevalence of cancer and the emergence of treatment resistance. This study addresses these challenges by focusing on Cyclin-dependent Kinase 2 (CDK2) and employing a systematic computational appr...

Full description

Saved in:
Bibliographic Details
Main Authors: Bharath Kumar Chagaleti, Venkatesan Saravanan, M. K. Kathiravan
Format: Article
Language:English
Published: SpringerOpen 2024-11-01
Series:Beni-Suef University Journal of Basic and Applied Sciences
Subjects:
Online Access:https://doi.org/10.1186/s43088-024-00577-8
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846147501738950656
author Bharath Kumar Chagaleti
Venkatesan Saravanan
M. K. Kathiravan
author_facet Bharath Kumar Chagaleti
Venkatesan Saravanan
M. K. Kathiravan
author_sort Bharath Kumar Chagaleti
collection DOAJ
description Abstract Background The global landscape of public health faces significant challenges attributed to the prevalence of cancer and the emergence of treatment resistance. This study addresses these challenges by focusing on Cyclin-dependent Kinase 2 (CDK2) and employing a systematic computational approach for the discovery of novel cancer therapeutics. Results Initial ligand-based pharmacophore modelling, utilizing a training set of five reported CDK2 inhibitors, yielded a robust model characterized by Aro|Hyd| and |Acc|Don| features. Screening this validated model against the ZINC database identified 1881 hits, which were further subjected to molecular docking studies. The top 10 compounds (Z1–Z10) selected from the docking studies underwent Pharmacokinetic parameters Absorption, Distribution, Metabolism, Excretion and Toxicity profiling, Density Functional Theory (DFT) studies and the top two went for 100ns molecular dynamics (MD) simulations by comparing them with the standard Roscovitine. Compounds Z1 and Z2 emerged as the most promising, with docking scores of − 8.05 kcal/mol and − 8.02 kcal/mol, respectively. DFT analysis of the top 10 compounds revealed minimal variations in highest occupied molecular orbital–lowest unoccupied molecular orbital energy gaps, indicating consistent electronic stability and reactivity across the candidates. MD simulations of Z1 and Z2 confirmed their stable interactions with CDK2, with root mean square deviation (RMSD) values ranging from 1.4 to 2.5 Å for Z1 and 1.5 to 2.4 Å for Z2. Conclusion The current research identified compounds Z1 and Z2, which demonstrated significant potential as potent CDK2 inhibitors for cancer therapy, providing valuable insights into the development of more effective CDK2 inhibitors and addressing the critical need for innovative therapeutic strategies in cancer treatment. Graphical abstract
format Article
id doaj-art-7134cd92c9f44ffbae5c492d81f75a0b
institution Kabale University
issn 2314-8543
language English
publishDate 2024-11-01
publisher SpringerOpen
record_format Article
series Beni-Suef University Journal of Basic and Applied Sciences
spelling doaj-art-7134cd92c9f44ffbae5c492d81f75a0b2024-12-01T12:40:04ZengSpringerOpenBeni-Suef University Journal of Basic and Applied Sciences2314-85432024-11-0113111910.1186/s43088-024-00577-8Discovery of novel CDK2 inhibitors for cancer treatment: integrating ligand-based pharmacophore modelling, molecular docking, DFT, ADMET, and molecular dynamics simulation studiesBharath Kumar Chagaleti0Venkatesan Saravanan1M. K. Kathiravan2Department of Pharmaceutical Chemistry, SRM College of Pharmacy, SRM Institute of Science and TechnologyDepartment of Pharmaceutical Chemistry, SRM College of Pharmacy, SRM Institute of Science and TechnologyDr A. P. J. Abdul Kalam Research Lab, Department of Pharmaceutical Chemistry, SRM College of Pharmacy, SRMISTAbstract Background The global landscape of public health faces significant challenges attributed to the prevalence of cancer and the emergence of treatment resistance. This study addresses these challenges by focusing on Cyclin-dependent Kinase 2 (CDK2) and employing a systematic computational approach for the discovery of novel cancer therapeutics. Results Initial ligand-based pharmacophore modelling, utilizing a training set of five reported CDK2 inhibitors, yielded a robust model characterized by Aro|Hyd| and |Acc|Don| features. Screening this validated model against the ZINC database identified 1881 hits, which were further subjected to molecular docking studies. The top 10 compounds (Z1–Z10) selected from the docking studies underwent Pharmacokinetic parameters Absorption, Distribution, Metabolism, Excretion and Toxicity profiling, Density Functional Theory (DFT) studies and the top two went for 100ns molecular dynamics (MD) simulations by comparing them with the standard Roscovitine. Compounds Z1 and Z2 emerged as the most promising, with docking scores of − 8.05 kcal/mol and − 8.02 kcal/mol, respectively. DFT analysis of the top 10 compounds revealed minimal variations in highest occupied molecular orbital–lowest unoccupied molecular orbital energy gaps, indicating consistent electronic stability and reactivity across the candidates. MD simulations of Z1 and Z2 confirmed their stable interactions with CDK2, with root mean square deviation (RMSD) values ranging from 1.4 to 2.5 Å for Z1 and 1.5 to 2.4 Å for Z2. Conclusion The current research identified compounds Z1 and Z2, which demonstrated significant potential as potent CDK2 inhibitors for cancer therapy, providing valuable insights into the development of more effective CDK2 inhibitors and addressing the critical need for innovative therapeutic strategies in cancer treatment. Graphical abstracthttps://doi.org/10.1186/s43088-024-00577-8CancerCDK2Pharmacophore modellingMolecular dockingDFTADMET
spellingShingle Bharath Kumar Chagaleti
Venkatesan Saravanan
M. K. Kathiravan
Discovery of novel CDK2 inhibitors for cancer treatment: integrating ligand-based pharmacophore modelling, molecular docking, DFT, ADMET, and molecular dynamics simulation studies
Beni-Suef University Journal of Basic and Applied Sciences
Cancer
CDK2
Pharmacophore modelling
Molecular docking
DFT
ADMET
title Discovery of novel CDK2 inhibitors for cancer treatment: integrating ligand-based pharmacophore modelling, molecular docking, DFT, ADMET, and molecular dynamics simulation studies
title_full Discovery of novel CDK2 inhibitors for cancer treatment: integrating ligand-based pharmacophore modelling, molecular docking, DFT, ADMET, and molecular dynamics simulation studies
title_fullStr Discovery of novel CDK2 inhibitors for cancer treatment: integrating ligand-based pharmacophore modelling, molecular docking, DFT, ADMET, and molecular dynamics simulation studies
title_full_unstemmed Discovery of novel CDK2 inhibitors for cancer treatment: integrating ligand-based pharmacophore modelling, molecular docking, DFT, ADMET, and molecular dynamics simulation studies
title_short Discovery of novel CDK2 inhibitors for cancer treatment: integrating ligand-based pharmacophore modelling, molecular docking, DFT, ADMET, and molecular dynamics simulation studies
title_sort discovery of novel cdk2 inhibitors for cancer treatment integrating ligand based pharmacophore modelling molecular docking dft admet and molecular dynamics simulation studies
topic Cancer
CDK2
Pharmacophore modelling
Molecular docking
DFT
ADMET
url https://doi.org/10.1186/s43088-024-00577-8
work_keys_str_mv AT bharathkumarchagaleti discoveryofnovelcdk2inhibitorsforcancertreatmentintegratingligandbasedpharmacophoremodellingmoleculardockingdftadmetandmoleculardynamicssimulationstudies
AT venkatesansaravanan discoveryofnovelcdk2inhibitorsforcancertreatmentintegratingligandbasedpharmacophoremodellingmoleculardockingdftadmetandmoleculardynamicssimulationstudies
AT mkkathiravan discoveryofnovelcdk2inhibitorsforcancertreatmentintegratingligandbasedpharmacophoremodellingmoleculardockingdftadmetandmoleculardynamicssimulationstudies